Neoadjuvant immune checkpoint therapy trialled for NSCLC

Two different phase 2 trials suggest most patients can go on to have full resection

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

Two phase 2 trials of preoperative immune checkpoint therapy have shown that it does not compromise surgery in patients with early non-small cell lung cancer (NSCLC).

Results of the two French trials — IONESCO and PRINCEPS — were reported at the European Society for Medical Oncology (ESMO) virtual congress 2020.

In IONESCO, 46 patients with early stage NSCLC were treated with three courses of the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab (750mg on days one, 15 and 29).

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .